Related Experiment Video
Updated: Nov 2, 2025
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
P2Y12 blocker monotherapy after percutaneous coronary intervention
F W A Verheugt1, P Damman2, S A J Damen2
1Department of Cardiology, Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands. f.w.a.verheugt@olvg.nl.
Insights
Dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) increases bleeding risk. P2Y12 blocker monotherapy significantly reduces major bleeding events compared to DAPT, without increasing ischemic risks.
Area of Science:
- Cardiology
- Interventional Cardiology
- Pharmacology
Background:
- Antiplatelet therapy is crucial for secondary prevention in coronary artery disease (CAD).
- Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 blocker is standard after percutaneous coronary intervention (PCI).
- DAPT increases bleeding risk compared to single antiplatelet therapy.
Purpose of the Study:
- To review current literature on P2Y12 blocker monotherapy as an alternative to DAPT after PCI.
- To evaluate the efficacy and safety of P2Y12 blocker monotherapy in reducing bleeding events.
- To compare P2Y12 blocker monotherapy with DAPT regarding ischemic outcomes.
Main Methods:
- Review of five randomized trials and two meta-analyses involving 32,181 stented patients.
- Comparison of outcomes between DAPT and P2Y12 blocker monotherapy.
- Analysis of major bleeding and ischemic events, including stent thrombosis.
Main Results:
- P2Y12 blocker monotherapy demonstrated a 50-60% reduction in major bleeding compared to DAPT.
- No significant increase in ischemic outcomes, such as stent thrombosis, was observed with P2Y12 blocker monotherapy.
- This approach offers a viable strategy to mitigate bleeding risk post-PCI.
Conclusions:
- P2Y12 blocker monotherapy is a safe and effective strategy for reducing bleeding after PCI.
- This therapeutic option balances the need for antithrombotic protection with a reduced risk of hemorrhage.
- Further research may solidify P2Y12 blocker monotherapy as a preferred strategy in select patient populations.
Abstract:
For secondary prevention of coronary artery disease (CAD) antiplatelet therapy is essential. For patients undergoing a percutaneous coronary intervention (PCI) temporary dual antiplatelet platelet therapy (DAPT: aspirin combined with a P2Y12 blocker) is mandatory, but leads to more bleeding than single antiplatelet therapy with aspirin. Therefore, to reduce bleeding after a PCI the duration of DAPT is usually kept as short as clinically acceptable; thereafter aspirin monotherapy is administered. Another option to reduce bleeding is to discontinue aspirin at the time of DAPT cessation and thereafter to administer P2Y12 blocker monotherapy. To date, five randomised trials have been published comparing DAPT with P2Y12 blocker monotherapy in 32,181 stented patients. Also two meta-analyses addressing this novel therapy have been presented. P2Y12 blocker monotherapy showed a 50-60% reduction in major bleeding when compared to DAPT without a significant increase in ischaemic outcomes, including stent thrombosis. This survey reviews the findings in the current literature concerning P2Y12 blocker monotherapy after PCI.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:27Peripheral Artery Disease III: Interprofessional Care
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:27Coronary Artery Disease V: Interprofessional Care
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...